Indokem (504092)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter sales of ₹42 Cr show the business still has a revenue base to build on.
• ROE of 10.38% is positive despite the profit decline, indicating some existing capital efficiency.
• Book value of ₹19.13 per share provides a tangible asset reference point.
• Market cap of ₹242 Cr is small, so a successful operational turnaround could offer meaningful upside.

Concerns

• Profit growth is -44.59% and latest quarter net profit is ₹0 Cr, leaving no current earnings power.
• Piotroski F-Score of 3/9 points to deteriorating fundamentals and possible financial strain.
• P/E of 284.32 and P/B of 4.54 offer no margin of safety at the current price.
• The 52-week range of ₹341.95–₹930.00 is inconsistent with a current price of ₹86.92, raising data or corporate-action ambiguity.

AI Analysis

Let me start with a confession: I cannot value a business when the numbers do not line up. Indokem trades at ₹86.92, but the quoted 52-week range of ₹341.95–₹930.00 sits far above that. Either the series has been restated, there was a corporate action, or the data is wrong. Before I can trust anything else, that must be explained. At ₹242 Cr market cap, the company has a book value of ₹19.13 per share, so I am being asked to pay 4.54 times book for a business earning a 10.38% ROE and a 7.38% ROCE. Those are mediocre numbers, not franchise returns. Sales are down 3.18%, profits are down 44.59%, and the latest quarter shows ₹42 Cr of revenue with zero net profit. That is not earnings power; it is a hope. A trailing P/E of 284.32 tells me the market is valuing a small or vanishing profit at a huge price. The Piotroski F-score of 3/9 reinforces my concern about financial health. There is no dividend, so there is no return while I wait. Promoter holding is not disclosed, which bothers me in a small-cap Indian chemical company. Graham taught me to buy with a margin of safety, not to pay a premium for what used to be good news. Specialty chemicals can have moats, but I see no evidence of pricing power or durable demand here. The balance sheet data on debt is missing, so I cannot even assess solvency. This looks more like a speculative turnaround than a value investment. I will only watch it from the sidelines until I see stabilised sales, genuine profits, a real balance sheet, and a price that gives me book value at a discount.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer